FFO
SKYE icon

Fortitude Family Office’s Skye Bioscience SKYE Stock Holding History

Fortitude Family Office’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-385
Closed -$289 – 2101
2025
Q4 		$289 Buy
385
+271
+238% +$396 ﹤0.01% 1828
2025
Q3 		$448 Buy
+114
New +$431 ﹤0.01% 1846

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Fortitude Family Office's SKYE Position: Q1 2026 in Review

Fortitude Family Office sold out of Skye Bioscience (SKYE) in Q1 2026, closing a stake of 385 shares — an estimated $289 sold.

Fortitude Family Office first reported a position in SKYE in Q3 2025 and held it in 2 quarters. The position peaked at $448 in Q3 2025. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Fortitude Family Office reported no remaining Skye Bioscience position as of Q1 2026 after selling out during the quarter.
  • Fortitude Family Office sold 385 Skye Bioscience shares in Q1 2026, an estimated $289.
  • Fortitude Family Office first reported a position in Skye Bioscience in Q3 2025 and held it in 2 quarters.
  • Fortitude Family Office's Skye Bioscience position peaked at $448 in Q3 2025.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.